SugarBud Craft Growers Corp.

DB:REL0 Stock Report

Market Cap: €499.6k

SugarBud Craft Growers Valuation

Is REL0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REL0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate REL0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate REL0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REL0?

Key metric: As REL0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for REL0. This is calculated by dividing REL0's market cap by their current revenue.
What is REL0's PS Ratio?
PS Ratio0.3x
SalesCA$2.24m
Market CapCA$718.58k

Price to Sales Ratio vs Peers

How does REL0's PS Ratio compare to its peers?

The above table shows the PS ratio for REL0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.6x
93M1 MPH Health Care
0.9x-60.2%€101.9m
B8FK Biofrontera
0.7xn/a€16.1m
KOAN Resonate Blends
0.4xn/aUS$602.4k
HMPS Hempsana Holdings
0.4xn/aCA$591.3k
REL0 SugarBud Craft Growers
0.3xn/a€718.6k

Price-To-Sales vs Peers: REL0 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (2.3x).

Price to Sales Ratio vs Industry

How does REL0's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x3.4%
REL0 SugarBud Craft Growers
 0.3xn/aUS$531.52k
REL0 0.3xIndustry Avg. 2.9xNo. of Companies33PS0612182430+
24 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x21.3%
REL0 SugarBud Craft Growers
 0.3xn/aUS$531.52k
No more companies

Price-To-Sales vs Industry: REL0 is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is REL0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REL0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate REL0's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.55

7D

-4.0%

1Y

78.7%

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.60

7D

5.7%

1Y

27.6%

Pharming Group

€491.5m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.70

7D

-0.7%

1Y

-34.1%